This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (15)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • HIV/AIDS  • Drug Therapy  • Drug Therapy, Other  • Genetics  • Genetics, Other  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Charles Flexner, MD

JAMA. 2000;283:2442-2444.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Fourteen antiretroviral drugs are now Food and Drug Administration (FDA)–approved for the treatment of human immunodeficiency virus (HIV) infection. Patients must take combination therapy perpetually because rapid virus turnover and high mutation rates promote drug resistance. The increasing prevalence of resistance has prompted development of drug resistance assays, and high-throughput techniques are now commercially available.

This issue of THE JOURNAL contains recommendations, developed by an international panel of experts, for the use and interpretation of anti-HIV drug resistance assays.¹ Two major analytic approaches are discussed: genotypic assays that identify particular mutations, usually point mutations, associated with resistance; and phenotypic assays that measure the ability of the patient's virus to grow in the presence of known concentrations of anti-HIV drugs. Although these techniques are scientifically sophisticated and exciting, they present dilemmas for the clinician and patient.

First, these assays are expensive. Despite automation, charges for a single genotypic . . . [Full Text of this Article]

Author Affiliation: Divisions of Clinical Pharmacology and Infectious Diseases, Departments of Medicine and Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, Md.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection: Recommendations of an International AIDS Society–USA Panel
Martin S. Hirsch, Françoise Brun-Vézinet, Richard T. D'Aquila, Scott M. Hammer, Victoria A. Johnson, Daniel R. Kuritzkes, Clive Loveday, John W. Mellors, Bonaventura Clotet, Brian Conway, Lisa M. Demeter, Stefano Vella, Donna M. Jacobsen, and Douglas D. Richman
JAMA. 2000;283(18):2417-2426.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

HIV Resistance Testing: an Update
Aslanzadeh
Annals of Clinical & Laboratory Science 2002;32:406-413.
ABSTRACT | FULL TEXT  

DPC 681 and DPC 684: Potent, Selective Inhibitors of Human Immunodeficiency Virus Protease Active against Clinically Relevant Mutant Variants
Kaltenbach et al.
Antimicrob. Agents Chemother. 2001;45:3021-3028.
ABSTRACT | FULL TEXT  

Population Genetic Analysis of the Protease Locus of Human Immunodeficiency Virus Type 1 Quasispecies Undergoing Drug Selection, Using a Denaturing Gradient-Heteroduplex Tracking Assay
Doukhan and Delwart
J. Virol. 2001;75:6729-6736.
ABSTRACT | FULL TEXT  

Human Immunodeficiency Virus Type 1 Drug Resistance Testing: a Comparison of Three Sequence-Based Methods
Erali et al.
J. Clin. Microbiol. 2001;39:2157-2165.
ABSTRACT | FULL TEXT  

HIV Resistance Testing in Clinical Practice: A QALY-fied Success
Saag
ANN INTERN MED 2001;134:475-477.
FULL TEXT  

Should Patients with Drug-Resistant HIV-1 Continue to Receive Antiretroviral Therapy?
Frenkel and Mullins
NEJM 2001;344:520-522.
FULL TEXT